Trial
NCT01628913
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Pancreatic Neuroendocrine Tumors (pNET)
Intervention
BEZ235
Why stopped
This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-07